CymaBay Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO CymaBay Therapeutics is Sujal Shah, benoemd in Mar2017, heeft een ambtstermijn van 6.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.56M, bestaande uit 23% salaris en 77% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.35% van de aandelen van het bedrijf, ter waarde $ 13.20M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 7 jaar.

Belangrijke informatie

Sujal Shah

Algemeen directeur

US$2.6m

Totale compensatie

Percentage CEO-salaris	23.0%
Dienstverband CEO	7yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	3.5yrs
Gemiddelde ambtstermijn bestuur	7yrs

Recente managementupdates

Recent updates

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Dec 22

Analyse CEO-vergoeding

Hoe is Sujal Shah's beloning veranderd ten opzichte van CymaBay Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2023	n/a	n/a	-US$105m
Sep 30 2023	n/a	n/a	-US$90m
Jun 30 2023	n/a	n/a	-US$81m
Mar 31 2023	n/a	n/a	-US$107m
Dec 31 2022	US$3m	US$590k	-US$106m
Sep 30 2022	n/a	n/a	-US$106m
Jun 30 2022	n/a	n/a	-US$104m
Mar 31 2022	n/a	n/a	-US$100m
Dec 31 2021	US$2m	US$550k	-US$90m
Sep 30 2021	n/a	n/a	-US$79m
Jun 30 2021	n/a	n/a	-US$68m
Mar 31 2021	n/a	n/a	-US$55m
Dec 31 2020	US$3m	US$510k	-US$51m
Sep 30 2020	n/a	n/a	-US$65m
Jun 30 2020	n/a	n/a	-US$80m
Mar 31 2020	n/a	n/a	-US$93m
Dec 31 2019	US$3m	US$510k	-US$103m
Sep 30 2019	n/a	n/a	-US$93m
Jun 30 2019	n/a	n/a	-US$85m
Mar 31 2019	n/a	n/a	-US$79m
Dec 31 2018	US$2m	US$452k	-US$73m
Sep 30 2018	n/a	n/a	-US$58m
Jun 30 2018	n/a	n/a	-US$48m
Mar 31 2018	n/a	n/a	-US$39m
Dec 31 2017	US$5m	US$393k	-US$28m

Compensatie versus markt: De totale vergoeding ($USD 2.56M ) Sujal } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.66M ).

Compensatie versus inkomsten: De vergoeding van Sujal is gestegen terwijl het bedrijf verliesgevend is.

CEO

Sujal Shah (50 yo)

7yrs

Tenure

US$2,561,783

Compensatie

Mr. Sujal A. Shah serves as Director at Tvardi Therapeutics, Inc. since January 2021. He has been the Chief Executive Officer and President of Cymabay Therapeutics, Inc, since November 6, 2017. Mr. Shah se...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sujal Shah	President	7yrs	US$2.56m	0.35% $ 13.2m
Charles McWherter	President of Research & Development and Chief Scientific Officer	11.2yrs	US$1.23m	0.041% $ 1.5m
Paul Quinlan	General Counsel	3.4yrs	US$1.10m	0.061% $ 2.3m
Harish Shantharam	CFO, Principal Accounting & Financial Officer	less than a year	geen gegevens	0.018% $ 653.5k
Ken Boehm	Senior Vice President of Human Resources	3.7yrs	geen gegevens	geen gegevens
Patrick O'Mara	Senior Vice President of Business Development	7.2yrs	geen gegevens	geen gegevens
Robert Martin	Senior Vice President of Manufacturing & Nonclinical Development	8.9yrs	geen gegevens	geen gegevens
Klara Dickinson-Eason	Chief Regulatory & Quality Assurance Officer	3.4yrs	US$1.24m	0.018% $ 681.8k
Becki Filice	Senior Vice President of Portfolio & Product Leadership	3.3yrs	geen gegevens	geen gegevens
Ben Kozub	Head of Commercial	less than a year	geen gegevens	geen gegevens

3.5yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CBAY wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sujal Shah	President	6.8yrs	US$2.56m	0.35% $ 13.2m
Thomas Wiggans	Independent Director	2.9yrs	US$207.94k	0% $ 0
Jerrold Olefsky	Member of Clinical Advisory Board and Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Caroline Loewy	Independent Director	7.3yrs	US$215.44k	0% $ 0
Mayer Davidson	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Robert Sherwin	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Gerald Shulman	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Morris Birnbaum	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Steven Shoelson	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Robert Gelfand	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
David Orloff	Member of Clinical Advisory Board	no data	geen gegevens	geen gegevens
Robert Wills	Independent Chairman	9yrs	US$245.44k	0.026% $ 974.1k

7.0yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CBAY wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).

CymaBay Therapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces Executive Changes

Cymabay Therapeutics, Inc. and Lewis Stuart, Chief Commercial Officer, Mutually Agrees on Cease to Be an Officer and Employee Effective December 29, 2023

President exercised options and sold US$973k worth of stock

President notifies of intention to sell stock

President exercised options and sold US$597k worth of stock

Recent updates

CymaBay Therapeutics Files Form 15

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

No longer forecast to breakeven

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Price target increased by 8.5% to US$31.07

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

Forecast to breakeven in 2026

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Cymabay Therapeutics, Inc. and Lewis Stuart, Chief Commercial Officer, Mutually Agrees on Cease to Be an Officer and Employee Effective December 29, 2023

Cymabay Therapeutics, Inc. Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis

President exercised options and sold US$973k worth of stock

President notifies of intention to sell stock

Price target increased by 7.5% to US$24.82

New minor risk - Profitability

CymaBay Therapeutics, Inc. Announces Publication of Two-Year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

President exercised options and sold US$597k worth of stock

General Counsel notifies of intention to sell stock

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $224.999939 million.

Price target increased by 17% to US$21.27

Insider notifies of intention to sell stock

Consensus revenue estimates increase by 156%

Price target increased by 8.0% to US$17.64

New minor risk - Profitability

CymaBay Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates fall by 15%

Price target increased by 8.5% to US$15.56

Insider notifies of intention to sell stock

Price target increased by 8.2% to US$14.67

New minor risk - Share price stability

Insider notifies of intention to sell stock

General Counsel notifies of intention to sell stock

Consensus revenue estimates fall by 40%

CymaBay Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

CymaBay Therapeutics, Inc. Appoints Harish Shantharam as Chief Financial Officer

Executive Officer notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Price target increased by 11% to US$13.56

Price target increased by 8.1% to US$11.63

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $84.999785 million.

CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01

CymaBay Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Cymabay Completes Enrollment for the Response Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

CymaBay: Long-Term Potential Based On Prior PBC Trial Results

CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from Russell 2000 Dynamic Index

CymaBay Therapeutics, Inc. Presents Positive PBC Data at the International Liver Congress 2022

President recently bought US$100k worth of stock

CymaBay Therapeutics, Inc. Presents New Findings That Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

Price target decreased to US$10.50

Insufficient new directors

CymaBay Therapeutics, Inc. Appoints Éric Lefebvre to the Audit Committee and the Nominating and Corporate Governance Committee of the Board

Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?

Chief Medical Officer recently bought US$61k worth of stock

Why I've Taken A 'Starter' Position In CymaBay Therapeutics

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

Cymabay Therapeutics, Inc. Announces Positive Data from Its Previously Completed Phase 2 Study and the Enhance Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis

We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth

Independent Director has left the company

Price target decreased to US$12.00

CymaBay Therapeutics, Inc. to Report Q4, 2020 Results on Mar 25, 2021

New 90-day low: US$5.32

We're Hopeful That CymaBay Therapeutics (NASDAQ:CBAY) Will Use Its Cash Wisely